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Abstract
Recent studies have demonstrated that differentiated somatic cells from various mammalian species can be
reprogrammed into induced pluripotent stem (iPS) cells by the ectopic expression of four transcription factors that
are highly expressed in embryonic stem (ES) cells. The generation of patient-specific iPS cells directly from somatic
cells without using oocytes or embryos holds great promise for curing numerous diseases that are currently
unresponsive to traditional clinical approaches. However, some recent studies have argued that various iPS cell
lines may still retain certain epigenetic memories that are inherited from the somatic cells. Such observations have
raised concerns regarding the safety and efficacy of using iPS cell derivatives for clinical applications. Recently, our
study demonstrated full pluripotency of mouse iPS cells by tetraploid complementation, indicating that it is
possible to obtain fully reprogrammed iPS cells directly from differentiated somatic cells. Therefore, we propose in
this review that further comprehensive studies of both mouse and human iPS cells are required so that additional
information will be available for evaluating the quality of human iPS cells.
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Introduction
An iPS cell is induced from a non-pluripotent cell, but
possesses pluripotency similar to that of ES cells. Taka-
hashi and Yamanaka (2006) first achieved this landmark
breakthrough by reprograming mouse embryonic fibro-
blasts (MEFs) into this new type of pluripotent stem cell
via the ectopic expression of only four transcription fac-
tors, namely Oct4, Sox2, Klf4 and c-Myc. This new pro-
cedure circumvented the need for an oocyte, which is
required by an earlier method of generating customized
pluripotent stem cells termed somatic cell nuclear trans-
fer (SCNT)-mediated nuclear reprogramming [1-3].
Since the discovery of iPS cells, the field has attracted a
great amount of scientific and public attention because
of the undefined mechanism by which the developmen-
tal potential of the cells is reverted and the potential for
clinical applications using patient specific iPS cells. The
generation of iPS cells from individual patients has
raised the hope of treatments for numerous degenerative
and genetic diseases [4-11].
Unlike normal fertilization or the generation of
SCNT-ES cells, the creation of iPS cells is a longer
process that results in a heterogeneous mixture of
cells with various developmental potentials. In the pri-
mary culture, iPS cells are usually present together
with the original somatic cells, transformed cells and
partially reprogrammed cells. Indeed, iPS cells are
only approximately 0.1% to 1% of the total cells used
for reprogramming. Moreover, only very small propor-
tions of these cells are fully reprogrammed based on
stringent criteria for evaluating pluripotency. There-
fore, it is necessary to establish a molecular standard
to distinguish fully reprogrammed iPS cells from those
that are partially reprogrammed, especially for human
iPS cells that may eventually be used for clinical
applications.
In the present review, we will summarize the most
recent progress toward understanding the pluripotency
of mouse iPS cells at the functional and molecular
levels. We anticipate that further studies will be under-
taken to improve our understanding of the determina-
tion and regulation of pluripotency in human iPS cells.
Differentiation Potential of Stem Cells
The capacity for differentiation into other cell types
under the appropriate conditions is the most important
property of early embryonic cells and stem cells. Based
on distinct differentiation capabilities, stem cells can be
subdivided into pluripotent, multipotent and unipotent
stem cells [12]. Only zygotes and the blastomeres of
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early embryos (before the 8-cell stage in mice) during
development possess totipotency. Totipotent embryos
differentiate into more than 200 types of cells that
belong to the three germ layers of development, as well
as extraembryonic tissues in vivo, thereby producing
new life. After this stage, blastomeres lose totipotency
and undergo the first cell fate determination. At the
blastocyst stage, a small number of blastomeres develop
into the pluripotent inner cell mass (ICM) and the rest
differentiate into trophectoderm that forms the extraem-
bryonic tissues and supports embryonic development.
The ICM differentiates further into the three germ
layers (ectoderm, mesoderm and endoderm) and then
into the entire body. This type of developmental capa-
city is termed pluripotency. Importantly, the ICM can
be isolated and maintained in vitro to derive ES cells,
which can be maintained in the same pluripotent state
as the ICM [13,14]. Numerous tissue-specific stem cells,
including hematopoietic stem cells, are multipotent and
can differentiate into various cell types within the same
cell lineage. The spermatogonial stem cell (SSC) is one
example of a unipotent tissue-specific stem cell, because
SSCs can only differentiate into spermatozoa.
The differentiation potential of stem cells is confirmed
by various differentiation assays. Multipotent and unipo-
tent stem cells should have the ability to differentiate into
specific cell types after transplantation under the appropri-
ate in vivo conditions or by in vitro culture with the appro-
priate stimuli. However, it is not practical to differentiate
pluripotent stem cells into all of the possible cell types of
an organism in vitro, although an embryoid body (EB) that
forms the three germ layers can be induced. Subcutaneous
transplantation of pluripotent stem cells into an immune
deficient mouse produces a teratoma. The formation of
teratomas has been used as the most preliminary assay for
testing the pluripotency of mouse pluripotent stem cells in
vivo. A more stringent assay for testing pluripotency is to
generate chimeric mice with a germ line transmission abil-
ity. However, the chimera assay may not convincingly
represent the full pluripotency of pluripotent stem cells.
Tetraploid blastocyst complementation remains the
most stringent assay for testing the pluripotency of plur-
ipotent stem cells. Tetraploid blastocysts are produced
via the fusion of 2-cell stage embryos and are develop-
mentally defective by only forming extraembryonic tis-
sues in vivo [15]. Interestingly, this developmental
characteristic of tetraploid embryos is exactly the oppo-
site of pluripotent stem cells. As expected, ES cells with
full pluripotency compensate for the developmental defi-
ciency of tetraploid embryos, and a full-term organism
can be produced from pluripotent stem cells together
with extraembryonic tissues derived from tetraploid
embryos (Figure 1A) [16,17]. In this manner, ES cells
differentiate into all of the various types of fetal cells,
tissues and organs, which organize into the organism
and truly demonstrate the pluripotency of ES cells. A
tetraploid complementation assay may also be consid-
ered a type of reconstruction assay similar to the multi-
potency test for hematopoietic stem cells, but the assay
reconstructs the whole fetus instead of only the hemato-
poietic system (Figure 1B). This information is more
useful than in vitro differentiation of stem cells because
it can clearly demonstrates that stem cells possess
greater potential for differentiation compared that of
other stem cell types.
Functional Evaluation of Mouse iPS Cell Pluripotency
The landmark achievement by Takahashi and Yamanaka
revealed that ectopic expression of four transcription fac-
tors in differentiated MEFs can induce nuclear reprogram-
ming to form iPS cells with a typical ES cell morphology.
These iPS cells express pluripotency genes and produce
teratomas following subcutaneous transplantation into
immune deficient nude mice. However, live chimeric mice
could not be produced by implanting the original iPS cells
into normal fertilized embryos [18]. Therefore, the original
iPS cells were not fully pluripotent iPS cells. Subsequently,
adult chimeras with germ line transmission ability were
generated from iPS cells with improved quality [19-21].
However, it remains uncertain whether fully pluripotent
iPS cells can be induced because full-term animals could
not be produced from iPS cells via tetraploid complemen-
tation, even with extensive efforts [21].
To demonstrate fully pluripotent iPS cells, numerous
iPS cell lines underwent tetraploid complementation
assays, and live pups were finally generated in three inde-
pendent laboratories including our own [22-24]. After
these studies were performed, the data collectively demon-
strated that iPS cells are functionally comparable with that
of ES cells. Follow-up experiments provided further evi-
dence that iPS cells derived from fetal somatic cells are
not the only type of inducible pluripotent cells. Indeed,
iPS cells derived from adult somatic cells can also be fully
pluripotent [25]. Furthermore, our recent studies have
shown that iPS cells that are reprogrammed with only
three factors (without c-Myc) can be fully pluripotent,
because viable mice can be produced entirely from the iPS
cells [26]. However, it should be noted that the success of
producing mice consisting of only iPS cells was likely due
to the large number of iPS cell lines being examined, and
the majority of iPS cell lines that were tested did not pro-
duce viable mice.
Differences between Fully Pluripotent iPS Cells and Non-
fully Pluripotent iPS Cells
To further characterize the differences between fully
pluripotent iPS cell lines and non-fully pluripotent iPS
cell lines, gene expression was compared between a
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Figure 1 Developmental potential of induced pluripotent stem (iPS) cells. A). Chimera and tetraploid embryo complementation assays for
evaluating the pluripotency of pluripotent stem cells. Chimeric mice are produced by aggregation of iPS cells with normal diploid embryos. For
tetraploid embryo complementation, the full-term organism is produced by iPS cells, whereas the extraembryonic placenta is derived from a
tetraploid embryo that is generated by electric fusion of a 2-cell stage embryo. B). Functional assays for evaluating the differentiation potential of
stem cells. Spermatogonial stem cells are unipotent stem cells and can differentiate into sperm as well as contribute toward formation of the
testes after transplantation. Hematopoietic stem cells are multipotent stem cells and can differentiate into various hematopoietic cells and
contribute toward bone marrow. Moreover, hematopoietic stem cells can reconstruct the entire hematopoietic system of irradiated mice. ES cells
are pluripotent stem cells and can theoretically differentiate into all cell types of an organism. Following transplantation into normal diploid
blastocysts, ES cells contribute toward the formation of all tissues of the chimera. Furthermore, ES cells can reconstruct the entire organism
following a tetraploid embryo complementation assay.
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variety of ES cells and iPS cell lines. A small number of
transcripts encoded within the imprinted Dlk1-Dio3
gene cluster on chromosome 12qF1, particularly Glt2
and Rian, are aberrantly silenced in most iPS cell lines
that poorly contribute toward chimeras and fail to sup-
port the development of iPS cell-derived organisms
using tetraploid embryo complementation [25,27]. In
contrast, fully pluripotent iPS cell lines exhibit normal
expression levels of these genes in this region. Subse-
quently, the gene expression status of this region has
been proposed as a candidate marker for evaluating the
quality of iPS cell lines.
However, silencing of the Dlk1-Dio3 gene cluster does
not appear to be the only underlying cause of incom-
plete pluripotency. Although the pluripotency of most
iPS cell lines that were tested correlated well with the
expression status of these genes, some exceptions
existed, in particular Oct4, Sox2 and Klf4 used to derive
iPS cell lines [26]. Moreover, the fact that Gtl2 knock-
out mice are viable challenges the importance of Gtl2 in
determining the pluripotency of iPS cells [28]. It has
been reported that treatment by a histone deacetylase
inhibitor reactivates the silenced Dlk1-Dio3 cluster in
partially reprogrammed iPS cells and rescues the ability
of iPS cells to support full-term development of iPS
cell-derived mice [25]. However, this study remains
debatable because the effects of the inhibitor are very
complicated. Therefore, we propose that the quality of
iPS cells may not be determined by only one gene clus-
ter, and that further comprehensive studies are neces-
sary for discovering additional candidate genes that may
synergistically contribute toward the quality of iPS cells.
We suggest that a comprehensive comparison of DNA
methylation, gene expression and non-coding RNAs
using mouse iPS cell lines derived from the same
somatic cells with varying developmental potentials
would provide a greater understanding of the regulation
of pluripotency. Additionally, a sample pool consisting
of various of iPS cell lines derived from multiple cell
types and derivation strategies with varying genetic
backgrounds should be analyzed to reach a consensus
(Figure 2).
Molecular Comparison of Human iPS Cells versus ES Cells
Unlike mouse iPS cells, in which pluripotency is tested
by tetraploid complementation assay, evaluating the
pluripotency of human iPS cells and ES cells is consid-
ered much more preliminary. Currently, the most strin-
gent assay for testing the pluripotency of human
pluripotent stem cells is teratoma formation, which only
evaluates the differentiation potential to form the three
germ layers or a small number of specific cell types, but
can not indicate full pluripotency. Recently, molecular
analyses of human ES cells and iPS cells using genome
wide high-throughput assays have allowed more quanti-
tative comparisons to be performed.
By comparing gene expression profiles, studies from
several independent groups have suggested that human
iPS cells generally resemble human ES cells, but some
recurrent differential gene expression signatures have
been observed [29-32]. These differences indicate both
insufficient silencing of donor cell-specific genes and
insufficient induction of ES cell-specific gene expression.
Furthermore, this original memory and incomplete
reprogramming appear to attenuate upon extended cul-
ture because late passage human iPS cells possess a
gene expression profile that is more similar to human
ES cells. However, these differential gene expression
profiles are considered to be stochastic and are affected
by the in vitro micro-environment. Upon the sample
pool being augmented, the two pluripotent cell types are
not consistently distinguished [33,34].
In addition to the transcriptional profiles, the differen-
tial methylation of specific CpG islands is suggested to
be distinguishable between human iPS cells and ES cells
[35]. Variations in CpG methylation, histone modifica-
tions and incomplete reprogramming of non-CpG
methylation regions that are proximal to centromeres
and telomeres in human iPS cells have been observed in
genome-wide profiles of DNA methylation at a single-
base resolution [36]. However, Guenther et al. (2010)
[33] confirmed that there is little difference between ES
cells and iPS cells with respect to genome-wide maps of
nucleosomes with histone H3K4 and H3K27 trimethyla-
tion, which supports the previous study of H3K4 and
H3K27 trimethylation levels in promoter regions [29].
In our opinion, there are several possibilities regarding
the cause of these controversies from studies that use
similar technologies. First, several studies have suggested
that passaging of iPS cells plays an important role in
determining the properties of iPS cells [29,37,38]. This
is understandable because early-passage iPS cell lines
may not have completed the reprogramming process. It
will be interesting to investigate whether this is true for
all iPS cell lines and if so, evaluation of the reprogram-
ming process should be extended to late passages, and
the characterization and application of iPS cells should
also be standardized with this aspect.
Second, analytical methods and data interpretation
greatly influence study conclusions. For example, the
threshold used for the calculation of statistical signifi-
cance can result in biases. Therefore, controversies
based on similar datasets suggest that any potential dif-
ferences between iPS cells and ES cells are very small.
Thus far, no specific significant group has been found.
Third, the properties of various iPS cell and ES cell
lines are stochastic. Varying conclusions can be drawn
because different cell lines, culture conditions and
Kang and Gao Journal of Animal Science and Biotechnology 2012, 3:5
http://www.jasbsci.com/content/3/1/5
Page 4 of 7
manipulations are used, and fluctuations can occur
within identical microenvironments. Therefore, we sug-
gest increasing the number of tested iPS cell lines to
reduce the variation caused by the inadequate compari-
sons between iPS cell lines.
Treating iPS Cells as ES Cells for Application
Although the derivation of iPS cells and ES cells is mark-
edly different, there are significant similarities between
them. However, a complication that researchers encoun-
ter in the application of iPS cells is the heterogenous
mixture of cells with various developmental potentials,
regardless of which derivation strategy is used. Irrespec-
tive of the similarity between fully reprogrammed iPS
cells and ES cells, incompletely reprogrammed iPS cells
remain present. Therefore, a major consideration for
clinical application of iPS cells in the future is to set the
minimum criteria to exclude low quality iPS cell lines.
In our opinion, it is not necessary to document the
similarity between human iPS cells and ES cells. Human
ES cells are also artificial products, and a gold standard
is not available for the evaluation of ES cell quality.
Clinically, normal cells that can efficiently differentiate
into particular cell types are required for regenerative
medicine. The use of transdifferentiation for direct con-
version of somatic cells into other types of somatic cells
has been proposed as an alternative strategy to obtain
functional cells for therapy [39-44]. However, the
Figure 2 Molecular analyses of iPS cells. High throughput analyses of mRNA, protein, DNA methylation and non-coding RNA of fully
pluripotent and non-fully pluripotent mouse iPS cells would assist our understanding of the pluripotency regulation of iPS cells. iPS cell lines
derived from the same somatic cell, but with varying differentiation potentials should be used, and a sample pool consisting of various iPS cell
groups derived from multiple cell types should be used to reach a consensus on iPS cell pluripotency.
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efficacy of the resultant cells would need to be con-
firmed that the shortened telomeres in aged cells are
elongated in the converted cells and if not, the useful-
ness of these cells for cell-based therapy would be
unclear. Thus, iPS cells remain the most attractive cell
source for clinical purposes.
We propose that the minimum requirements for the
clinical use of human iPS cells are: 1) a normal karyo-
type, because some sub-karyotypic alterations are
observed during reprogramming and a normal karyotype
is an important factor for ES cell characterization; 2) a
normal genotype. Human iPS cell derivation strategies
should be improved to preserve the integrity of donor
cells, and the method applied without transgenes to
include mRNA and protein-mediated induction assisted
by small molecules [45,46]; 3) the activation of pluripo-
tency networks. This would ensure that iPS cells possess
the necessary self-renewal ability and differentiation
potential; and 4) a specific differentiation ability. This is
the most important criteria and represents the useful-
ness of iPS cells for specific cell-based therapies.
The epigenetic memory from the original donor cells in
incompletely reprogrammed iPS cells would affect the dif-
ferentiation tendency of early-passage iPS cells [37,38]. As
previously discussed, iPS cell lines that are stably main-
tained to late passages should be used. A small number of
iPS cell lines have exhibited reduced differentiation effi-
ciencies toward a particular cell type [47], and cell-line-
specific differences in DNA methylation and gene expres-
sion profiles could lead to an in vitro differentiation pro-
pensity [48]. Then, primary exclusion may have a positive
effect by increasing the differentiation efficiency, but more
convenient examination standards should be applied.
Conclusion
The direct reprogramming of differentiated somatic cells
into iPS cells has enabled us to investigate the molecular
events during cell fate choice, as well as the potential
clinical use of iPS cells to cure numerous diseases. We
have demonstrated the full pluripotency of mouse iPS
cells in a functional manner via tetraploid complementa-
tion. However, molecular standards for distinguishing
iPS cells with various pluripotencies remain to be estab-
lished. Thus, further comprehensive studies are required
for improving our understanding of the regulation of
pluripotency within mouse iPS cells. More importantly,
similar studies to compare human iPS cells will provide
information to establish minimal molecular criteria for
evaluating the quality of human iPS cells in the future.
Acknowledgements
We thank colleagues in our laboratory for their insightful comments. This
study was supported by the Ministry of Science and Technology of China
(grants 2008AA022311, 2010CB944900 and 2011CB964800).
Authors’ contributions
LK and SG wrote and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 28 December 2011 Accepted: 28 February 2012
Published: 28 February 2012
References
1. Campbell KH, et al: Sheep cloned by nuclear transfer from a cultured cell
line. Nature 1996, 380:64-6.
2. Wilmut I, et al: Viable offspring derived from fetal and adult mammalian
cells. Nature 1997, 385:810-3.
3. Hochedlinger K, Jaenisch R: Nuclear transplantation, embryonic stem
cells, and the potential for cell therapy. N Engl J Med 2003, 349:275-86.
4. Hanna J, et al: Treatment of sickle cell anemia mouse model with iPS
cells generated from autologous skin. Science 2007, 318:1920-3.
5. Dimos JT, et al: Induced pluripotent stem cells generated from patients
with ALS can be differentiated into motor neurons. Science 2008,
321:1218-21.
6. Park IH, et al: Disease-specific induced pluripotent stem cells. Cell 2008,
134:877-86.
7. Wernig M, et al: Neurons derived from reprogrammed fibroblasts
functionally integrate into the fetal brain and improve symptoms of rats
with Parkinson’s disease. Proc Natl Acad Sci USA 2008, 105:5856-61.
8. Ebert AD, et al: Induced pluripotent stem cells from a spinal muscular
atrophy patient. Nature 2009, 457:277-80.
9. Lee G, et al: Modelling pathogenesis and treatment of familial
dysautonomia using patient-specific iPSCs. Nature 2009, 461:402-6.
10. Raya A, et al: Disease-corrected haematopoietic progenitors from Fanconi
anaemia induced pluripotent stem cells. Nature 2009, 460:53-9.
11. Soldner F, et al: Parkinson’s disease patient-derived induced pluripotent
stem cells free of viral reprogramming factors. Cell 2009, 136:964-77.
12. Jaenisch R, Young R: Stem cells, the molecular circuitry of pluripotency
and nuclear reprogramming. Cell 2008, 132:567-82.
13. Evans MJ, Kaufman MH: Establishment in culture of pluripotential cells
from mouse embryos. Nature 1981, 292:154-6.
14. Thomson JA, et al: Embryonic stem cell lines derived from human
blastocysts. Science 1998, 282:1145-7.
15. Tarkowski AK, et al: Development of cytochalasin in B-induced tetraploid
and diploid/tetraploid mosaic mouse embryos. J Embryol Exp Morphol
1977, 41:47-64.
16. Nagy A, et al: Embryonic stem cells alone are able to support fetal
development in the mouse. Development 1990, 110:815-21.
17. Nagy A, et al: Derivation of completely cell culture-derived mice from
early-passage embryonic stem cells. Proc Natl Acad Sci USA 1993,
90:8424-8.
18. Takahashi K, Yamanaka S: Induction of pluripotent stem cells from mouse
embryonic and adult fibroblast cultures by defined factors. Cell 2006,
126:663-76.
19. Maherali N, et al: Directly reprogrammed fibroblasts show global
epigenetic remodeling and widespread tissue contribution. Cell Stem Cell
2007, 1:55-70.
20. Okita K, et al: Generation of germline-competent induced pluripotent
stem cells. Nature 2007, 448:313-7.
21. Wernig M, et al: In vitro reprogramming of fibroblasts into a pluripotent
ES-cell-like state. Nature 2007, 448:318-24.
22. Boland MJ, et al: Adult mice generated from induced pluripotent stem
cells. Nature 2009, 461:91-4.
23. Kang L, et al: iPS cells can support full-term development of tetraploid
blastocyst-complemented embryos. Cell Stem Cell 2009, 5:135-8.
24. Zhao XY, et al: iPS cells produce viable mice through tetraploid
complementation. Nature 2009, 461:86-90.
25. Stadtfeld M, et al: Aberrant silencing of imprinted genes on chromosome
12qF1 in mouse induced pluripotent stem cells. Nature 2010, 465:175-81.
26. Kang L, et al: Viable mice produced from three-factor induced
pluripotent stem (iPS) cells through tetraploid complementation. Cell Res
2011, 21:546-9.
27. Liu L, et al: Activation of the imprinted Dlk1-Dio3 region correlates with
pluripotency levels of mouse stem cells. J Biol Chem 2010, 285:19483-90.
Kang and Gao Journal of Animal Science and Biotechnology 2012, 3:5
http://www.jasbsci.com/content/3/1/5
Page 6 of 7
28. Takahashi N, et al: Deletion of Gtl2, imprinted non-coding RNA, with its
differentially methylated region induces lethal parent-origin-dependent
defects in mice. Hum Mol Genet 2009, 18:1879-88.
29. Chin MH, et al: Induced pluripotent stem cells and embryonic stem cells
are distinguished by gene expression signatures. Cell Stem Cell 2009,
5:111-23.
30. Marchetto MC, et al: Transcriptional signature and memory retention of
human-induced pluripotent stem cells. PLoS ONE 2009, 4:e7076.
31. Chin MH, et al: Molecular analyses of human induced pluripotent stem
cells and embryonic stem cells. Cell Stem Cell 2010, 7:263-9.
32. Ghosh Z, et al: Persistent donor cell gene expression among human
induced pluripotent stem cells contributes to differences with human
embryonic stem cells. PLoS ONE 2010, 5:e8975.
33. Guenther MG, et al: Chromatin structure and gene expression programs
of human embryonic and induced pluripotent stem cells. Cell Stem Cell
2010, 7:249-57.
34. Newman AM, Cooper JB: Lab-specific gene expression signatures in
pluripotent stem cells. Cell Stem Cell 2010, 7:258-62.
35. Doi A, et al: Differential methylation of tissue- and cancer-specific CpG
island shores distinguishes human induced pluripotent stem cells,
embryonic stem cells and fibroblasts. Nat Genet 2009, 41:1350-3.
36. Lister R, et al: Hotspots of aberrant epigenomic reprogramming in
human induced pluripotent stem cells. Nature 2011, 471:68-73.
37. Kim K, et al: Epigenetic memory in induced pluripotent stem cells. Nature
2010, 467:285-90.
38. Polo JM, et al: Cell type of origin influences the molecular and functional
properties of mouse induced pluripotent stem cells. Nat Biotechnol 2010,
28:848-55.
39. Weintraub H, et al: Activation of muscle-specific genes in pigment, nerve,
fat, liver, and fibroblast cell lines by forced expression of MyoD. Proc
Natl Acad Sci USA 1989, 86:5434-8.
40. Zhou Q, et al: In vivo reprogramming of adult pancreatic exocrine cells
to beta-cells. Nature 2008, 455:627-32.
41. Hanna JH, et al: Pluripotency and cellular reprogramming: facts,
hypotheses, unresolved issues. Cell 2010, 143:508-25.
42. Ieda M, et al: Direct reprogramming of fibroblasts into functional
cardiomyocytes by defined factors. Cell 2010, 142:375-86.
43. Szabo E, et al: Direct conversion of human fibroblasts to multilineage
blood progenitors. Nature 2010, 468:521-6.
44. Vierbuchen T, et al: Direct conversion of fibroblasts to functional neurons
by defined factors. Nature 2010, 463:1035-41.
45. Kim D, et al: Generation of human induced pluripotent stem cells by
direct delivery of reprogramming proteins. Cell Stem Cell 2009, 4:472-6.
46. Warren L, et al: Highly efficient reprogramming to pluripotency and
directed differentiation of human cells with synthetic modified mRNA.
Cell Stem Cell 2010, 7:618-30.
47. Hu BY, et al: Neural differentiation of human induced pluripotent stem
cells follows developmental principles but with variable potency. Proc
Natl Acad Sci USA 2010, 107:4335-40.
48. Bock C, et al: Reference Maps of Human ES and iPS Cell Variation Enable
High-Throughput Characterization of Pluripotent Cell Lines. Cell 2011,
144:439-52.
doi:10.1186/2049-1891-3-5
Cite this article as: Kang and Gao: Pluripotency of induced pluripotent
stem cells. Journal of Animal Science and Biotechnology 2012 3:5.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Kang and Gao Journal of Animal Science and Biotechnology 2012, 3:5
http://www.jasbsci.com/content/3/1/5
Page 7 of 7
